Posted October 21, 2009
Dr. Syd Coleman was the lead author in a paper that demonstrated that cryolipolysis treatment can cause substantial reductions in subcutaneous fat volume and changes in the contour of the treated love handle without damage to the skin or underlying tissues. The Zeltiq device has not been approved by the FDA for the purposes discussed in the paper.
Read MorePosted September 22, 2009
The FDA has approved the Zeltiq device in a 510(K) application. Dr. Syd Coleman was the lead author in a paper that demonstrated that cryolipolysis treatment can cause substantial reductions in subcutaneous fat volume and changes in the contour of the treated love handle without damage to the skin or underlying tissues. The Zeltiq device has not been approved by the FDA for the purposes discussed in the paper.
Read MorePosted June 24, 2009
Sydney Coleman of New York City is the lead author on the first study published on the effectiveness and safety of cryolipolysis, a progressive method of programming fat to die. The study demonstrated significant and safe reductions in lovehandle fat deposits treated with the non-invasive fat technology from Zeltiq.
Read MorePosted August 12, 2008
Zeltiq Aesthetics has developed a breakthrough biotechnology for reducing unwanted fat. The Zeltiq device uses cryolipolysis to precisely cool fat and induce lipolysis (the breakdown of fat) apparently without any permanent damage to other tissues (skin, nerves, muscle and bone) around the fat. The technology allows for natural body sculpting. Harvard Medical School and Massachusetts […]
Read More
